

Peter C M Van De Kerkhof

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7221253/publications.pdf>

Version: 2024-02-01

215
papers

7,251
citations

66250

44
h-index

93651

72
g-index

222
all docs

222
docs citations

222
times ranked

6310
citing authors

#	ARTICLE	IF	CITATIONS
1	Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1591-1597.	1.1	4
2	Exploring patient journeys through acne healthcare: a patient perspective. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2209-2216.	1.1	4
3	Predictors of surgical treatment burden, outcomes, and overall survival in older adults with basal cell carcinoma: Results from the prospective, multicenter BATO cohort. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1010-1019.	0.6	9
4	Optimizing shared decision making in older adults with basal cell carcinoma: experiences from a specialized outpatient clinic. <i>British Journal of Dermatology</i> , 2022, 186, 589-591.	1.4	2
5	Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. <i>Dermatology and Therapy</i> , 2022, 12, 61-78.	1.4	18
6	Foreword. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 3-4.	3.3	0
7	Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2680-2684.	1.1	4
8	Dermatology in a changing world. <i>Journal of Dermatological Treatment</i> , 2022, 33, 605-605.	1.1	1
9	From Empirical to Pathogenesis-Based Treatments for Psoriasis. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1778-1785.	0.3	28
10	Frailty screening in dermatology practice: a modified Delphi study and a systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 95-104.	1.3	12
11	Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. <i>British Journal of Dermatology</i> , 2021, 184, 640-651.	1.4	16
12	Quality of life, treatment goals, preferences and satisfaction in older adults with psoriasis: a patient survey comparing age groups. <i>British Journal of Dermatology</i> , 2021, 184, 759-762.	1.4	11
13	Vasculature in the Margin of the Psoriatic Lesion. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 106-112.	0.3	0
14	Pioneers in Dermatology and Venereology: An Interview with Professor Peter van de Kerkhof. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1041-1042.	1.3	0
15	Structure, quality and accessibility of the Dutch acne healthcare; a care providers' perspective. <i>Journal of Dermatological Treatment</i> , 2021, 32, 269-276.	1.1	2
16	Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1-11.	1.3	7
17	Future perspectives on care for patients with psoriasis. What did we learn during the COVID-19. <i>Journal of Dermatological Treatment</i> , 2021, 32, 477-477.	1.1	1
18	Reallocations in acne healthcare: exploring the possible roles and added value of non-physicians by a mixed-methods study design. <i>BMC Health Services Research</i> , 2021, 21, 746.	0.9	0

#	ARTICLE	IF	CITATIONS
19	The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis. <i>British Journal of Dermatology</i> , 2021, 185, 879-879.	1.4	1
20	Evaluation of Watchful Waiting and Tumor Behavior in Patients With Basal Cell Carcinoma. <i>JAMA Dermatology</i> , 2021, 157, 1174.	2.0	16
21	Treatment goals in psoriasis from a patient perspective: a qualitative study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 13-17.	1.1	18
22	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 117-122.	0.6	120
23	Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 119-126.	1.3	15
24	Our ambition in a changing landscape of psoriasis treatments. <i>Journal of Dermatological Treatment</i> , 2020, 31, 105-107.	1.1	0
25	Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients. <i>JAMA Dermatology</i> , 2020, 156, 72.	2.0	14
26	Effectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults. <i>JAMA Dermatology</i> , 2020, 156, 1229.	2.0	16
27	Dermatology before, during and after COVID 19. <i>Journal of Dermatological Treatment</i> , 2020, 31, 435-435.	1.1	0
28	Phototherapy in the perspective of the chronicity of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 926-931.	1.3	8
29	Translational Research and Drug Development in Psoriasis by Collaborative Efforts of Academia and Industry. <i>Journal of Investigative Dermatology</i> , 2020, 140, 524-526.	0.3	1
30	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 839-846.	0.6	78
31	Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 393.	2.0	29
32	Disease and Treatment Characteristics in Geriatric Psoriasis: A Patient Survey Comparing Age Groups. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00215.	0.6	11
33	Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00340.	0.6	13
34	The effect of adalimumab on the vasculature in psoriatic skin lesions. <i>Journal of Dermatological Treatment</i> , 2019, 30, 221-226.	1.1	12
35	A cross-sectional study in young adults with psoriasis: potential determining factors in quality of life, life course and work productivity. <i>Journal of Dermatological Treatment</i> , 2019, 30, 208-215.	1.1	22
36	Psoriasis dermatitis: an overlap condition of psoriasis and atopic dermatitis in children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e74-e76.	1.3	15

#	ARTICLE	IF	CITATIONS
37	Development of a Novel Approach to Studying Corneodesmosomes and Stratum Corneum Adhesion: Extending Knowledge on the Pathophysiology of Sensitive Skin. <i>Skin Pharmacology and Physiology</i> , 2019, 32, 81-93.	1.1	2
38	Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 699-709.	3.3	5
39	The association of scalp psoriasis with overall psoriasis severity and koebnerization in children: cross-sectional findings from the Dutch Child CAPTURE registry. <i>British Journal of Dermatology</i> , 2019, 181, 1099-1101.	1.4	4
40	Augmentation of Understanding in Clinical Practise and Big Data Analytics. <i>Dermatology</i> , 2019, 235, 253-254.	0.9	0
41	Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e352-e353.	1.3	3
42	Economic evaluation of a tailored therapist-guided internet-based cognitive behavioural treatment for patients with psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2019, 181, 614-616.	1.4	3
43	The dynamics of endothelial changes in vivo following standardized skin injury. <i>Skin Research and Technology</i> , 2019, 25, 618-624.	0.8	1
44	Severity, heterogeneity and systemic inflammation in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 643-647.	1.3	43
45	Biosimilars for Psoriasis: Experience from Europe. <i>Current Dermatology Reports</i> , 2019, 8, 26-34.	1.1	6
46	Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. <i>British Journal of Dermatology</i> , 2019, 180, 67-75.	1.4	33
47	Effects of red light on inflammation and skin barrier recovery following acute perturbation. Pilot study results in healthy human subjects. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2019, 35, 275-276.	0.7	0
48	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 70-79.e3.	0.6	77
49	Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification – rationale and design of the randomized, multicenter STEPI study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1930-1939.	1.3	40
50	The efficacy and safety of non-pharmacological therapies for the treatment of acne vulgaris: A systematic review and best-evidence synthesis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1195-1203.	1.3	31
51	Prevalence of genital psoriasis in patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 754-760.	1.1	36
52	The load tolerance of skin during impact on artificial turf using ex-vivo skin as the readout system. <i>Science and Medicine in Football</i> , 2018, 2, 39-46.	1.0	0
53	Effects of blue light on inflammation and skin barrier recovery following acute perturbation. Pilot study results in healthy human subjects. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2018, 34, 184-193.	0.7	20
54	The journey of adult psoriasis patients towards biologics: past and present – Results from the BioCAPTURE registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 615-623.	1.3	24

#	ARTICLE	IF	CITATIONS
55	Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. <i>Journal of Dermatological Treatment</i> , 2018, 29, 220-229.	1.1	14
56	Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 3-14.	1.3	76
57	The Dermatologist and psoriatic arthritis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1836-1837.	1.3	0
58	The value of (video)dermoscopy in the diagnosis and monitoring of common inflammatory skin diseases: a systematic review. <i>European Journal of Dermatology</i> , 2018, 28, 575-596.	0.3	9
59	Treatment failure in superficial basal cell carcinoma following treatment with photodynamic therapy: is this a result of underdiagnosis?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e50-e52.	1.3	3
60	Psoriasis and Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2017, 7, 31-41.	1.4	60
61	A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1176-1182.	1.3	10
62	Sensitive skin and the influence of female hormone fluctuations: results from a cross-sectional digital survey in the Dutch population. <i>European Journal of Dermatology</i> , 2017, 27, 42-48.	0.3	18
63	Treatment Adherence Intervention Studies in Dermatology and Guidance on How to Support Adherence. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 253-271.	3.3	49
64	Subclinical enthesitis in nail psoriasis patients: a case-control study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 405-412.	0.4	8
65	Subklinische Enthesitis bei Nagelpsoriasis-Patienten: eine Fall-Kontroll-Studie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 405-413.	0.4	3
66	Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 477-482.	1.3	71
67	Risk factors associated with sensitive skin and potential role of lifestyle habits: a cross-sectional study. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 656-658.	0.6	13
68	Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1867-1875.	1.3	12
69	Guideline-based clinical decision support in acne patients receiving isotretinoin: improving adherence and cost-effectiveness. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e440-e442.	1.3	1
70	Response of the Endothelium to the Epicutaneous Application of Leukotriene B ₄ . <i>Skin Pharmacology and Physiology</i> , 2017, 30, 306-314.	1.1	5
71	Use of oral antidepressants in patients with chronic pruritus: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 1068-1073.e7.	0.6	60
72	Cognitive Schemas in Placebo and Nocebo Responding: Role of Autobiographical Memories and Expectations. <i>Clinical Therapeutics</i> , 2017, 39, 502-512.e1.	1.1	14

#	ARTICLE	IF	CITATIONS
73	Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial. <i>BMC Dermatology</i> , 2017, 17, 6.	2.1	15
74	Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm [®] - and placebo-controlled trial (BRIDGE). <i>British Journal of Dermatology</i> , 2017, 176, 615-623.	1.4	111
75	Polymorphisms in <i>CD84</i> , <i>IL12B</i> and <i>TNFAIP3</i> are associated with response to biologics in patients with psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 1288-1296.	1.4	42
76	Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry. <i>British Journal of Dermatology</i> , 2017, 176, 1001-1009.	1.4	45
77	Validation of the Simplified Psoriasis Index in Dutch children and adolescents with plaque psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 771-776.	1.4	10
78	The Epidemiology and Clinicopathological Features of Basal Cell Carcinoma in Patients 80 Years and Older. <i>JAMA Dermatology</i> , 2017, 153, 71.	2.0	38
79	Predictors of perceived stigmatization in patients with psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 687-694.	1.4	63
80	Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort. <i>British Journal of Dermatology</i> , 2017, 176, 786-793.	1.4	37
81	Measurement of skin surface biomarkers by Transdermal Analyses Patch following different <i>in vivo</i> models of irritation: a pilot study. <i>Skin Research and Technology</i> , 2017, 23, 336-345.	0.8	14
82	Minimizing nocebo effects by conditioning with verbal suggestion: A randomized clinical trial in healthy humans. <i>PLoS ONE</i> , 2017, 12, e0182959.	1.1	56
83	Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t. <i>British Journal of Dermatology</i> , 2016, 175, 340-347.	1.4	65
84	A four-phase strategy for the implementation of reflectance confocal microscopy in dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1308-1314.	1.3	7
85	Tailored Therapist-Guided Internet-Based Cognitive Behavioral Treatment for Psoriasis: A Randomized Controlled Trial. <i>Psychotherapy and Psychosomatics</i> , 2016, 85, 297-307.	4.0	44
86	Comment on "Review of patient registries in dermatology". <i>Journal of the American Academy of Dermatology</i> , 2016, 75, e241.	0.6	1
87	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 83-98.e4.	0.6	264
88	Improving the applicability of guidelines on nonmelanoma skin cancer in frail older adults: a multidisciplinary expert consensus and systematic review of current guidelines. <i>British Journal of Dermatology</i> , 2016, 175, 1003-1010.	1.4	19
89	Comparison of the Dermatology Life Quality Index and the Children's Dermatology Life Quality Index in assessment of quality of life in patients with psoriasis aged 16-17 years. <i>British Journal of Dermatology</i> , 2016, 174, 152-157.	1.4	36
90	Placebo and nocebo effects on itch: effects, mechanisms, and predictors. <i>European Journal of Pain</i> , 2016, 20, 8-13.	1.4	42

#	ARTICLE	IF	CITATIONS
91	Values and costs in the management of psoriasis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 393-394.	1.1	0
92	An outpatient multidisciplinary training programme for children and adolescents with psoriasis and their parents: a pilot study. <i>European Journal of Dermatology</i> , 2016, 26, 393-395.	0.3	7
93	Skin cancer care in institutionalized elderly in the Netherlands: a nationwide study on the role of nursing home physicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, e236-e237.	1.3	7
94	Fumaric acid esters in recalcitrant pediatric psoriasis: A prospective, daily clinical practice case series. <i>Journal of Dermatological Treatment</i> , 2016, 27, 214-220.	1.1	19
95	Implicit stigmatization-related biases in individuals with skin conditions and their significant others.. <i>Health Psychology</i> , 2016, 35, 861-865.	1.3	26
96	Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2002-2010.	1.3	139
97	Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children's quality of life in daily practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1193-1197.	1.3	26
98	Prioritizing dermatoses: rationally selecting guideline topics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1636-1640.	1.3	4
99	Clearing of psoriasis documented by laser Doppler perfusion imaging contrasts remaining elevation of dermal expression levels of CD31. <i>Skin Research and Technology</i> , 2015, 21, 340-345.	0.8	13
100	Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. <i>Lancet, The</i> , 2015, 386, 552-561.	6.3	350
101	The value of <i>in vivo</i> reflectance confocal microscopy in the diagnosis and monitoring of inflammatory and infectious skin diseases: a systematic review. <i>British Journal of Dermatology</i> , 2015, 172, 1222-1248.	1.4	48
102	Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the BioCAPTURE registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 560-565.	1.3	37
103	Systemic treatments in paediatric psoriasis: a systematic evidence-based update. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 425-437.	1.3	41
104	Placebo Effects on Itch: A Meta-Analysis of Clinical Trials of Patients with Dermatological Conditions. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1234-1243.	0.3	83
105	Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease. <i>British Journal of Dermatology</i> , 2015, 172, 722-728.	1.4	60
106	Current Dermatologic Care in Dutch Nursing Homes and Possible Improvements: A Nationwide Survey. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 714.e1-714.e6.	1.2	11
107	Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. <i>Paediatric Drugs</i> , 2015, 17, 373-384.	1.3	160
108	â€œPatient-centered treatmentâ€ for mild-to-moderate psoriasis. <i>Journal of Dermatological Treatment</i> , 2015, 26, 1-6.	1.1	7

#	ARTICLE	IF	CITATIONS
109	Drug Survival Studies in Dermatology: Principles, Purposes, and Pitfalls. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1-5.	0.3	79
110	Noninvasive differentiation between stable and unstable chronic plaque psoriasis using <i>in vivo</i> reflectance confocal microscopy. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 870-872.	0.6	8
111	A national study on adherence to a basal cell carcinoma guideline; development of a tool to assess guideline adherence. <i>British Journal of Dermatology</i> , 2015, 172, 1008-1013.	1.4	8
112	How to personalize the treatment of psoriasis with biologics?. <i>Journal of Dermatological Treatment</i> , 2015, 26, 101-102.	1.1	0
113	Dermatological exposure to coal tar and bladder cancer risk: A case-control study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 20.e19-20.e22.	0.8	16
114	An increased risk of non-melanoma skin cancer during <i>in vivo</i> TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 752-760.	1.3	51
115	An Update on Topical Therapies for Mild-Moderate Psoriasis. <i>Dermatologic Clinics</i> , 2015, 33, 73-77.	1.0	33
116	Dermatology: Where are We Coming from and Where are We Going to?. <i>Frontiers in Medicine</i> , 2014, 1, 40.	1.2	0
117	Happy™ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the Bio-CAPTURE network. <i>British Journal of Dermatology</i> , 2014, 171, 1189-1196.	1.4	89
118	Unmet needs in the treatment of psoriasis. <i>European Journal of Dermatology</i> , 2014, 24, 523-532.	0.3	24
119	Whole field laser Doppler imaging of the microcirculation in psoriasis and clinically unaffected skin. <i>Journal of Dermatological Treatment</i> , 2014, 25, 18-21.	1.1	22
120	Role of Conditioning and Verbal Suggestion in Placebo and Nocebo Effects on Itch. <i>PLoS ONE</i> , 2014, 9, e91727.	1.1	105
121	Understanding the Acute Skin Injury Mechanism Caused by Player-Surface Contact During Soccer. <i>Orthopaedic Journal of Sports Medicine</i> , 2014, 2, 232596711453348.	0.8	18
122	Establishing the dynamics of neutrophil accumulation <i>in vivo</i> by reflectance confocal microscopy. <i>Experimental Dermatology</i> , 2014, 23, 184-188.	1.4	21
123	Increased prevalence of psoriasis in patients with coronary artery disease. <i>British Journal of Dermatology</i> , 2014, 171, 450-450.	1.4	1
124	The psychophysiological stress response in psoriasis and rheumatoid arthritis. <i>British Journal of Dermatology</i> , 2014, 170, 824-831.	1.4	26
125	Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network. <i>British Journal of Dermatology</i> , 2014, 170, 1158-1165.	1.4	28
126	The effect of adalimumab on key drivers in the pathogenesis of psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 571-580.	1.4	20

#	ARTICLE	IF	CITATIONS
127	The effectiveness and safety of short-contact dithranol therapy in paediatric psoriasis: a prospective comparison of regular day care and day care with telemedicine. <i>British Journal of Dermatology</i> , 2014, 170, 454-457.	1.4	39
128	Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: Bio CAPTURE. <i>British Journal of Dermatology</i> , 2014, 171, 1091-1098.	1.4	20
129	Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with autoimmune inflammatory rheumatic diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 27-33.	1.3	34
130	Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 415-424.	1.4	39
131	Are Newly Discovered Drivers of Immune-Mediated Skin Disorders Expressed in Normal Skin Regenerating from Standardized Surface Injury?. <i>Dermatology</i> , 2014, 228, 255-260.	0.9	11
132	The prevalence of onychomycosis in psoriatic patients: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 533-541.	1.3	71
133	Cutaneous Application of Leukotriene B ₄ as an in vivo Model of Psoriasis-Like Skin Inflammation: An Immunohistological Study. <i>Skin Pharmacology and Physiology</i> , 2014, 27, 120-126.	1.1	15
134	Scoring nail psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 1061-1066.	0.6	46
135	In Vivo Induction of Cutaneous Inflammation Results in the Accumulation of Extracellular Trap-Forming Neutrophils Expressing ROR γ t and IL-17. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1276-1284.	0.3	107
136	Immune responses to stress in rheumatoid arthritis and psoriasis. <i>Rheumatology</i> , 2014, 53, 1844-1848.	0.9	20
137	Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort. <i>British Journal of Dermatology</i> , 2014, 171, 363-369.	1.4	33
138	New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 264-270.	1.3	20
139	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 871-881.e30.	0.6	423
140	Nail Psoriasis, the unknown burden of disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1690-1695.	1.3	58
141	Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 593-600.	1.3	32
142	Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 399-410.	1.3	19
143	Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 931-951.	1.3	32
144	Long-term management of scalp psoriasis: perspectives from the international psoriasis council. <i>Journal of Dermatological Treatment</i> , 2013, 24, 188-192.	1.1	19

#	ARTICLE	IF	CITATIONS
145	Nail psoriasis: a questionnaire-based survey. <i>British Journal of Dermatology</i> , 2013, 169, 314-319.	1.4	74
146	Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin. <i>British Journal of Dermatology</i> , 2013, 168, 1294-1302.	1.4	40
147	Innovations in the treatment of psoriasis and non-melanoma skin cancers. <i>Journal of Dermatological Treatment</i> , 2013, 24, 161-161.	1.1	0
148	THU0590â€¦The Patient-Therapist Relationship as An Indicator for Treatment Success in E-Health Treatments for Patients with Rheumatoid Arthritis and Psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A364.2-A364.	0.5	0
149	Apremilast: a step forward in the treatment of psoriasis?. <i>Lancet, The</i> , 2012, 380, 708-709.	6.3	2
150	Paediatric-onset psoriasis is associated with <i>ERAP1</i> and <i>IL23R</i> loci, <i>LCE3C_LCE3B</i> deletion and <i>HLA-C*06</i> . <i>British Journal of Dermatology</i> , 2012, 167, 922-925.	1.4	31
151	Efficacy of blue light vs. red light in the treatment of psoriasis: a double-blind, randomized comparative study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 219-225.	1.3	47
152	Safety of treatment with biologics for psoriasis in daily practice: 5-year data. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 283-291.	1.3	34
153	Role of induced negative and positive emotions in sensitivity to itch and pain in women. <i>British Journal of Dermatology</i> , 2012, 167, 262-269.	1.4	42
154	Reflectance confocal microscopy: an effective tool for monitoring ultraviolet B phototherapy in psoriasis. <i>British Journal of Dermatology</i> , 2012, 167, 396-403.	1.4	32
155	The influence of treatments in daily clinical practice on the Children's Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry. <i>British Journal of Dermatology</i> , 2012, 167, 145-149.	1.4	51
156	A framework for improving the quality of care for people with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1-16.	1.3	42
157	Is "class effect" relevant when assessing the benefit/risk profile of a biologic agent?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 9-16.	1.3	9
158	Improving clinical trial design in psoriasis: Perspectives from the global dermatology community. <i>Journal of Dermatological Treatment</i> , 2011, 22, 187-193.	1.1	4
159	F175 ROLE OF NEGATIVE AND POSITIVE EMOTIONS IN SENSITIVITY TO PAIN AND ITCH. <i>European Journal of Pain Supplements</i> , 2011, 5, 124-124.	0.0	0
160	The International Psoriasis Council Presents Top Five Psoriasis Research Articles for July 2010â€"December 2010. <i>Psoriasis Forum</i> , 2011, 17a, 275-279.	0.1	0
161	Long-term, continuous dosing of etanercept in patients with plaque psoriasis. <i>Expert Review of Dermatology</i> , 2011, 6, 361-373.	0.3	1
162	Juvenile psoriasis in European and Asian children: similarities and differences. <i>British Journal of Dermatology</i> , 2011, 164, 1101-1103.	1.4	43

#	ARTICLE	IF	CITATIONS
163	Management of palmoplantar pustulosis: do we need to change?. <i>British Journal of Dermatology</i> , 2011, 164, 942-946.	1.4	68
164	Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the international psoriasis council. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1130-1139.	1.3	31
165	I use sunscreens but is it really safe under the sun?. <i>Journal of Dermatological Treatment</i> , 2011, 22, 61-61.	1.1	0
166	Acitretin revisited in the era of biologics. <i>Journal of Dermatological Treatment</i> , 2011, 22, 86-89.	1.1	37
167	Pustulosis palmoplantaris is a disease distinct from psoriasis. <i>Journal of Dermatological Treatment</i> , 2011, 22, 102-105.	1.1	70
168	No evidence found that childhood onset of psoriasis influences disease severity, future body mass index or type of treatments used. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1333-1339.	1.3	33
169	Novel biologic therapies in development targeting IL-12/IL-23. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 5-9.	1.3	8
170	Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. <i>British Journal of Dermatology</i> , 2010, 163, 838-846.	1.4	45
171	A cross-sectional study using the Children's Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores. <i>British Journal of Dermatology</i> , 2010, 163, 1099-1101.	1.4	72
172	The values of treatments for chronic inflammatory skin diseases; challenges of the market of health. <i>Journal of Dermatological Treatment</i> , 2010, 21, 1-2.	1.1	3
173	Topical treatments in dermatology still going strong. <i>Journal of Dermatological Treatment</i> , 2010, 21, 125-125.	1.1	0
174	Expression of p14 ARF, p16 INK4a and p53 in relation to HPV in (pre-)malignant squamous skin tumours. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 2148-2157.	1.6	11
175	Induction of protoporphyrin IX by aminolaevulinic acid in actinic keratosis, psoriasis and normal skin: preferential porphyrin enrichment in differentiated cells. <i>British Journal of Dermatology</i> , 2009, 160, 849-857.	1.4	23
176	Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. <i>British Journal of Dermatology</i> , 2009, 160, 670-675.	1.4	72
177	Individual differences in the effect of daily stressors on psoriasis: a prospective study. <i>British Journal of Dermatology</i> , 2009, 161, 295-299.	1.4	76
178	Textbook of Atopic Dermatitis. <i>Journal of Dermatological Treatment</i> , 2009, 20, 70-70.	1.1	0
179	A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. <i>British Journal of Dermatology</i> , 2008, 158, 375-381.	1.4	29
180	Psoriasis: consensus on topical therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 859-870.	1.3	29

#	ARTICLE	IF	CITATIONS
181	Period of remission after treatment with UVA in sclerodermic skin diseases. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 839-844.	1.3	24
182	Analysis of 3-year national reimbursement application data on etanercept and efalizumab for psoriasis. British Journal of Dermatology, 2008, 159, 760-761.	1.4	4
183	Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. British Journal of Dermatology, 2008, 159, ???-???.	1.4	149
184	Options for the treatment of psoriasis: a multifactorial approach. Clinics in Dermatology, 2008, 26, 419-423.	0.8	7
185	Psoriasis of the face and flexures. Journal of Dermatological Treatment, 2007, 18, 351-360.	1.1	33
186	A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation. British Journal of Dermatology, 2007, 156, 130-137.	1.4	16
187	Oral retinoic acid metabolism blocking agent Rambazole for plaque psoriasis: an immunohistochemical study. British Journal of Dermatology, 2007, 156, 263-270.	1.4	31
188	The evolution of the psoriatic lesion. British Journal of Dermatology, 2007, 157, 4-15.	1.4	39
189	The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument. British Journal of Dermatology, 2007, 158, 071115063928006-???.	1.4	89
190	Sedentary patients with venous or mixed leg ulcers: determinants of physical activity. Journal of Advanced Nursing, 2007, 60, 50-57.	1.5	27
191	Oral R115866 in the treatment of moderate to severe plaque-type psoriasis. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 1038-1046.	1.3	34
192	Effect of calcipotriol on epidermal cell populations in alefacept-treated psoriatic lesions. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 27-33.	1.3	9
193	Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 639-650.	1.3	35
194	The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 060628090810004-???.	1.3	29
195	Therapeutic effects of a 12-week course of alefacept on nail psoriasis. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 1252-1255.	1.3	36
196	Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatologic Therapy, 2006, 19, 252-263.	0.8	84
197	Efficacy of the pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis: a comparative study. British Journal of Dermatology, 2006, 155, 110-114.	1.4	31
198	Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. British Journal of Dermatology, 2006, 154, 880-884.	1.4	89

#	ARTICLE	IF	CITATIONS
199	A placebo-controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolaevulinic acid-photodynamic therapy in patients with psoriasis. <i>British Journal of Dermatology</i> , 2006, 155, 429-436.	1.4	48
200	Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid: an immunohistochemical study. <i>British Journal of Dermatology</i> , 2006, 155, 539-545.	1.4	33
201	A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. <i>British Journal of Dermatology</i> , 2006, 155, 800-807.	1.4	35
202	Assessment of epidermal subpopulations and proliferation in healthy skin, symptomless and lesional skin of spreading psoriasis. <i>British Journal of Dermatology</i> , 2006, 155, 688-694.	1.4	30
203	Evidence-based and patient-based dermatology. <i>Journal of Dermatological Treatment</i> , 2006, 17, 197-197.	1.1	0
204	Current and future treatment options for acne. <i>Journal of Dermatological Treatment</i> , 2006, 17, 198-204.	1.1	16
205	Quality of life in vitiligo patients after treatment with long-term narrowband ultraviolet B phototherapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 56-60.	1.3	20
206	Recommendations for the topical treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 495-499.	1.3	12
207	Follicular cysts and hyperkeratoses as first manifestation, and involvement of the central nervous system as late manifestation of mycosis fungoides. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 777-779.	1.3	10
208	Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation. <i>British Journal of Dermatology</i> , 2005, 153, 72-78.	1.4	99
209	Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. <i>British Journal of Dermatology</i> , 2005, 152, 1275-1281.	1.4	176
210	The topical treatment of psoriasis. <i>Clinical and Experimental Dermatology</i> , 2005, 30, 205-208.	0.6	11
211	Alefacept in the Treatment of Psoriasis in Patients for Whom Conventional Therapies Are Inadequate. <i>Dermatology</i> , 2005, 211, 256-263.	0.9	18
212	A Two-Compound Product Containing Calcipotriol and Betamethasone Dipropionate Provides Rapid, Effective Treatment of Psoriasis vulgaris regardless of Baseline Disease Severity. <i>Dermatology</i> , 2005, 210, 294-299.	0.9	28
213	The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (DaivobetR/ DovobetR) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2004, 151, 663-668.	1.4	50
214	Established Treatments of Psoriasis. <i>Inflammation and Allergy: Drug Targets</i> , 2004, 3, 145-156.	3.1	17
215	Age-based treatment differences in and reluctance to treating older adults with systemic antipsoriatic therapy – a mixed-method pilot study. <i>Journal of Dermatological Treatment</i> , 0, , 1-9.	1.1	0